RBC Capital Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM)

RBC Capital analyst Brian Abrahams maintained a Buy rating on Contineum Therapeutics, Inc. Class A today and set a price target of $25.00. The company’s shares closed yesterday at $11.93.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Abrahams is a 3-star analyst with an average return of 2.4% and a 46.12% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Gilead Sciences, and PTC Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Contineum Therapeutics, Inc. Class A with a $23.60 average price target, a 97.82% upside from current levels. In a report released on September 26, Leerink Partners also initiated coverage with a Buy rating on the stock with a $20.00 price target.

Based on Contineum Therapeutics, Inc. Class A’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $16.04 million. In comparison, last year the company had a GAAP net loss of $9.01 million